Boston – June 13, 2022 – Cooley advised Biospring Partners, a growth equity firm exclusively focused on business-to-business (B2B) life sciences technology companies, on the closing of its debut fund with more than $245 million in capital commitments, which includes related co-investment vehicles managed and/or advised by Biospring Partners. Partners Nicole Peppe and Lina Zhou led the Cooley team advising Biospring Partners.
Through its new fund, Biospring Partners aims to invest in companies with the potential to fundamentally shift how technology is utilized across the life sciences sector.
Founded in 2020, Biospring Partners leverages its deep experience to support B2B software, tools and biopharma services companies that are driving innovation across the life sciences industry and beyond. Founded and led by women, the firm is well positioned to partner with life sciences technology companies that have the potential to fundamentally change the research, diagnosis and treatment of disease.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe.